Abstract
Numerous signaling pathways are involved in the molecular pathogenesis of melanoma. Two of the most prominent pathways include the RAS-RAF-MEK-ERK pathway and the PI3K-AKT pathway. While targeted inhibition of BRAF/MEK have resulted in improved survival in patients with BRAF V600-mutated melanoma, therapeutic resistance is often the end result. The PI3K-AKT pathway plays a significant role in BRAF-/MEK-inhibitor resistance in melanoma patients and may represent a crucial target for combination therapy. This chapter will describe the components of the PI3K-AKT pathway, highlight their role in cellular physiology and melanoma pathogenesis, and examine their potential for molecular-targeted therapy.
Cite
CITATION STYLE
Siroy, A. E., Davies, M. A., & Lazar, A. J. (2016). The PI3K-AKT Pathway in Melanoma. In Genetics of Melanoma (pp. 165–180). Springer New York. https://doi.org/10.1007/978-1-4939-3554-3_7
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
